Patents by Inventor Alan R. Fritzberg

Alan R. Fritzberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110269943
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.
    Type: Application
    Filed: June 28, 2010
    Publication date: November 3, 2011
    Applicants: University of Washington, Poniard Pharmaceuticals, Inc.
    Inventors: Sudhakar Kasina, John M. Reno, Alan R. Fritzberg, Jonathan Tait
  • Patent number: 7744853
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: June 29, 2010
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventors: Sudhakar Kasina, John M. Reno, Alan R. Fritzberg, Jonathan Tait
  • Patent number: 7696331
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: April 13, 2010
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Patent number: 7691985
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: April 6, 2010
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventor: Alan R. Fritzberg
  • Patent number: 7605239
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: October 20, 2009
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventor: Alan R. Fritzberg
  • Publication number: 20090136419
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Application
    Filed: June 19, 2008
    Publication date: May 28, 2009
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Publication number: 20080279773
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Application
    Filed: March 6, 2008
    Publication date: November 13, 2008
    Inventor: Alan R. Fritzberg
  • Patent number: 7408046
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: August 5, 2008
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Patent number: 7385042
    Abstract: One embodiment provides a composition comprising a) a compound of formula I: wherein R1, X and n have any of the values described in the specification, or a pharmaceutically acceptable salt thereof; b) a radionuclide; and c) a radioprotectant.
    Type: Grant
    Filed: July 13, 2006
    Date of Patent: June 10, 2008
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventor: Alan R. Fritzberg
  • Patent number: 7378077
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: May 27, 2008
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventors: Alan R. Fritzberg, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Patent number: 7115720
    Abstract: The invention provides a complex comprising a) a compound formula I: wherein R1, X and n have any of the values described in the specification, or a pharmaceutically acceptable salt thereof; and b) a radionuclide. The complexes are useful as diagnostic agents and as therapeutic agents. The invention also provides methods and intermediates useful for preparing the complexes of the invention, as well as therapeutic and diagnostic methods.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: October 3, 2006
    Assignee: Neorx Corporation
    Inventor: Alan R. Fritzberg
  • Patent number: 7097823
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: February 23, 2004
    Date of Patent: August 29, 2006
    Assignee: NEORX Corporation
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Patent number: 7094885
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: June 20, 2003
    Date of Patent: August 22, 2006
    Assignee: NeoRx Corporation
    Inventor: Alan R. Fritzberg
  • Patent number: 7070759
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: July 4, 2006
    Assignee: NeoRx Corporation
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Publication number: 20040241172
    Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.
    Type: Application
    Filed: February 10, 2004
    Publication date: December 2, 2004
    Applicant: NeoRx Corporation
    Inventors: Donald B. Axworthy, Louis J. Theodore, Linda M. Gustavson, John M. Reno, Robert W. Mallett, Mark D. Hylarides, Alan R. Fritzberg
  • Patent number: 6767531
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: July 27, 2004
    Assignee: NeoRx Corporation
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Publication number: 20040126317
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Application
    Filed: June 20, 2003
    Publication date: July 1, 2004
    Inventor: Alan R. Fritzberg
  • Publication number: 20040096393
    Abstract: The invention provides a complex comprising a) a compound formula I: 1
    Type: Application
    Filed: July 8, 2003
    Publication date: May 20, 2004
    Inventor: Alan R. Fritzberg
  • Publication number: 20020176818
    Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
    Type: Application
    Filed: December 11, 2001
    Publication date: November 28, 2002
    Inventors: Alan R. Fritzberg, Paul G. Abrams, Lauren Marie Tatalick, Kent R. Thoelke, James Kyle Bryan, Mark D. Hylarides, Elizabeth K. John
  • Publication number: 20020137672
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.
    Type: Application
    Filed: July 30, 2001
    Publication date: September 26, 2002
    Inventors: Sudhakar Kasina, John M. Reno, Alan R. Fritzberg, Jonathan Tait